Knowledge Center

Churchill Downs Announces Stock Split, Higher Dividend, and New Share Repurchase Program

On October 31, Churchill Downs Inc. (CHDN) made three important corporate financial announcements. First, the company announced that it would increase its annual dividend to shareholders by 7%. Second, the Board of Directors authorized a 3-for-1 stock split. Third, the Board of Directors approved a new $300 million share repurchase program.   Sonal notified subscribers […]

Read more...

Kratos Defense and Security Solutions Awarded $15.2 Million Contract

Kratos Defense and Security Solutions, Inc. (KTOS) announced on November 8 that the company has received contract awards totaling approximately $15.2 million. The contract is for high performance unmanned aerial drones, unmanned ground, and unmanned system products and services. Kratos is a leading provider of National Security Solutions.     Sonal received the news and […]

Read more...

October 2018 Scorecard

The October 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Unifi Announces New Share Repurchase Program

On October 31, Unifi, Inc. (UFI) announced that the company’s Board of Directors authorized a new stock repurchase program. The Board of Directors terminated the previous program, which had been in place since April 2014. The new program authorizes management to repurchase up to $50 million of the company’s common stock. Sonal detected the event […]

Read more...

NeoGenomics to Acquire Genoptix

NeoGenomics, Inc. (NEO) announced on October 23 that the company has entered into a definitive agreement to acquire Genoptix, Inc. NeoGenomics will pay $125 million in cash plus 1 million shares of NeoGenomics common stock according to the agreement. Genoptix is a leading clinical oncology laboratory, and NeoGenomics is the leading provider of cancer-focused genetic […]

Read more...

Ameris Bancorp Announces New Stock Repurchase Program

On October 25, Ameris Bancorp (ABCB) announced that its Board of Directors authorized a new share repurchase program. Under this program, Ameris Bancorp can repurchase up to $100 million in common shares over the next 12 months. Ameris Bancorp is a bank holding company with branch locations in Georgia, Florida, Alabama, and South Carolina.   […]

Read more...

Canopy Growth Corp. to Buy Ebbu’s Hemp Research Assets

Canopy Growth Corporation (CPC) announced on October 15 that the company would purchase the intellectual property and assets of Ebbu Inc for CAD 25 million plus 6.2 million shares. Canopy Growth is a Canadian pot company, and Ebbu is a Colorado-based hemp research company. CPC hopes to reduce its production costs by implementing technology developed […]

Read more...

September 2018 Scorecard

The September 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Paratek Receives FDA Approval of NUZYRA to Treat Bacterial Pneumonia and Skin Infections

On October 2, Paratek Pharmaceuticals, Inc. (PRTK) announced that the company received FDA approval of NUZYRA™ (omadacycline) to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA is an antibiotic that can be administered either orally or through a once-daily IV treatment. Paratek plans to have the drug available in […]

Read more...

Seattle Genetics and Takeda Pharmaceuticals Report Positive Topline Phase 3 Clinical Trial Results

On October 1, Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE) reported results from their phase 3 clinical trial of ECELON-2. The trial demonstrated a statistically significant improvement in progression-free survival for patients using their drug Adcentris in combination with chemotherapy when compared to chemotherapy alone. It is the first randomized Phase 3 […]

Read more...